The most common grade @-@ immune-related adverse events in the ipilimumab group were gastrointestinal ( @ -LSB- @ % -RSB- vs four -LSB- < @ % -RSB- in the placebo group ) , hepatic ( @ -LSB- @ % -RSB- vs one -LSB- < @ % -RSB- ) , and endocrine ( @ -LSB- @ % -RSB- vs none ) .